FDA Oncology Announcements

FLT3 inhibitor × Myeloid × Clear all

3 Announcements

FDA approves quizartinib for newly diagnosed acute myeloid leukemia

Trial: QuANTUM-First
Drug: Vanflyta (quizartinib) · FLT3 inhibitor
Conditions: MyeloidOther hematologic neoplasm

FDA approves addition of survival data to gilteritinib label for refractory AML with a FLT3 mutation

Drug: XOSPATA (gilteritinib) · FLT3 inhibitor
Condition: Myeloid

FDA approves gilteritinib for relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutatation

Drug: XOSPATA (gilteritinib) · FLT3 inhibitor
Conditions: MyeloidOther hematologic neoplasm